Top-5 Cardiovascular Trial Site - Southeast US
Seven active Phase 1-3 cardiovascular trials. Sixteen pharma sponsors including Alnylam, Pfizer, and Pharmacosmos. GCSA-certified. Led by the U.S. TAVR pioneer. Sponsors get audit-ready data on schedule. Patients get tomorrow's standard of care, today, at no cost.
Led by Dr. William O'Neill -- pioneer of TAVR in the United States
10
Active Trials Now
16+
Pharma Partners
Top 5
CV Site in Southeast US
15+
Years of Experience
Leadership
Performed the first TAVR in the United States — now leading clinical trial science at Amavita Research.
Our leadership team combines pioneering interventional expertise with proven clinical research execution.
Chief Medical OfficerChief Medical Officer & Senior Principal Investigator
Internationally renowned interventional cardiologist and pioneer in structural heart disease. Medical Director, Center for Structural Heart Disease, Henry Ford Hospital · Chief Medical Advisor, CardioElite™. Performed the first TAVR in the United States and served as National Principal Investigator for the Edwards PARTNER, Protect II, and Protect IV trials.
Co-Investigator · Cardiology Lead · Founder & CEO, amavita Heart and Vascular Health®
Harvard-trained interventional cardiologist with 15+ years of experience and 25+ clinical research trials, including pivotal work helping develop the Trans-Caval TAVR approach. Founder and CEO of amavita Heart and Vascular Health®.
Head of Growth & Strategy
Drives growth strategy and sponsor relationships at Amavita Research. CEO of bioaccess® with 20+ years scaling clinical research operations across Latin America and the U.S.
Affiliated ASCOur Surgical Center Advantage
The only ambulatory surgery center of its kind in South Florida.
Amavita Research patients and sponsor trials have direct access to Advanced Cardiovascular of Miami — South Florida's only dedicated cardiovascular and interventional-radiology ambulatory surgery center. A next-generation cath lab built for advanced same-day procedures.
9408 SW 87th Ave., Suite 303, Miami, FL 33176
Active Studies
Investigating tomorrow's standards of care across cardiology, hypertension, and vascular medicine.
Treatment-Resistant Hypertension
Alnylam ALN-AGT01-008
Phase 3 evaluation of zilebesiran, an investigational RNAi therapeutic targeting AGT, for adults with treatment-resistant hypertension and elevated cardiovascular risk.
Eligibility & detailsAcute Coronary Syndrome
Pfizer C4921003
Pivotal Phase 3 study evaluating a novel antithrombotic strategy in patients following an acute coronary syndrome event.
Eligibility & detailsHeart Failure (across EF ranges)
JK07201
Novel heart failure therapy under investigation across the spectrum of ejection fraction, including HFrEF, HFmrEF, and HFpEF.
Eligibility & detailsIron-Deficient Heart Failure
Phase 3 evaluation of intravenous ferric derisomaltose in patients with heart failure and iron deficiency to improve outcomes and quality of life.
Eligibility & detailsHFpEF
First-in-human evaluation of VS-041, a novel mechanism targeting cardiac structural remodeling in heart failure with preserved ejection fraction.
Eligibility & detailsHFpEF (Metabolic Therapy)
Metabolic-pathway therapy under investigation for symptomatic improvement in heart failure with preserved ejection fraction.
Eligibility & detailsPeripheral Artery Disease
Pivotal evaluation of an advanced peripheral atherectomy system for treatment of calcified lower-extremity arterial disease.
Eligibility & detailsTrusted by leading sponsors
16+ pharmaceutical and biotech partners — selection shown
For Patients
For Sponsors
FAQ
Quick answers about clinical trials, leadership, location, and what participation involves at Amavita Research.
Insights
Plain-language education on clinical trials, conditions, and procedures — written for patients and partners.
For Patients
From the first phone call through the final follow-up visit, here is a step-by-step look at what participating in a cardiovascular clinical trial actually involves.
Read moreClinical Research Basics
Drug clinical trials are organized into phases. Each one answers different safety and effectiveness questions. Here is what each phase is for, in plain language.
Read moreClinical Research Basics
First-in-human (FIH) trials are the first time a new therapy is studied in people. Here is how protocols, oversight, and site experience combine to keep participants safe.
Read moreWhether you are a patient seeking new treatment options or a sponsor planning your next study, our team is ready to help.